Telomeric Abnormalities in Colorectal Diseases by Fluorescent in Situ Hybridization Technique
NCT ID: NCT03208777
Last Updated: 2017-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
80 participants
OBSERVATIONAL
2017-08-01
2019-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* These findings could suggest that changes in TL may take place before the development of the tumor .
The two main forms of inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's disease (CD) are characterized by chronic intestinal inflammation and risk of progression to colon cancer. One proposed cause of the latter characteristic is chromosome instability, since the rearrangement of genetic material can lead to activation of oncogenes, loss of tumor suppressor genes and other changes that lead to uncontrolled cell growth. Chromosome instability is particularly associated with UC and has been observed in colon epithelial cells and peripheral blood mononuclear cell. Since genomic instability in peripheral blood mononuclear cells (PBMCs) has been used as a biomarker for global cancer risk in a number of diseases, the latter observation suggests the possibility of a chromosome instability syndrome in UC that could affect all tissues. One possible cause of chromosome instability is telomere dysfunction .
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Presence of Circulating Tumor DNA in Colorectal Cancer
NCT01198743
A Comparison of Different Fecal Occult Blood Test for Colorectal Cancer Screening
NCT04454099
Association Between ABO Polymorphism and Gastric/Colorectal Cancers
NCT06149923
A Multi-center Trial to Establish a Model for the Early Diagnosis of Colorectal Cancer by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNA
NCT03676075
Evaluation of a Model for the Early Diagnosis of Colorectal Cancer by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNA to the Community Colorectal Cancer Screening Program
NCT05638243
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
fluorescent in situ hybridization is a molecular diagnostic technique that utilizes labeled DNA probes to detect or confirm gene or chromosome abnormalities. fluorescent in situ hybridization is often utilized for both research and diagnosis of hematological malignancies and solid tumors. Conceptually, fluorescent in situ hybridization is a very straightforward technique whereby a DNA probe is hybridized to its complementary sequence on chromosomal preparations previously fixed on microscope slides . fluorescent in situ hybridization is able to detect cells that have chromosomal abnormalities consistent with neoplasia .
There has been a surge of published studies which assessed the association between telomere length and development of colorectal carcinoma. Thus, a meta-analysis addressing colorectal carcinoma and telomere length would be a useful addition to the current information in this area.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
control group
taking blood samples from apparently healthy people
taking blood samples
taking blood samples and measure telomeric abnormalities
benign colorectal
taking blood samples from patients
taking blood samples
taking blood samples and measure telomeric abnormalities
malignant colorectal
taking blood samples from patients
taking blood samples
taking blood samples and measure telomeric abnormalities
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
taking blood samples
taking blood samples and measure telomeric abnormalities
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Newly diagnosed cases (no previous treatment).
* No treatment was taken for HCV infection.
Exclusion Criteria
* Patients with malignancy of other type.
* Patients not diagnosed by endoscopy or biopsy (not surely diagnosed).
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
fatma magdy zidan
principle investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
fatma magdy zidan, residant
Role: PRINCIPAL_INVESTIGATOR
South Egypt Cancer Institute
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Bosman F, Yan P. Molecular pathology of colorectal cancer. Pol J Pathol. 2014 Dec;65(4):257-66. doi: 10.5114/pjp.2014.48094.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FISH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.